Engelsk titel: Independent clinical trials are imperative
Läs online
Författare:
Götzsche PC
Email: pcg@cochrane.dk
Språk: Dan
Antal referenser: 37
Dokumenttyp:
Översikt
UI-nummer: 05041499
Sammanfattning
It is undesirable that the pharmaceutical industry designs, analyses and writes reports on trials whose aim is to show whether new drugs are better than existing treatments. It has been shown that manipulation in all phases of the research process occurs, e.g., in the design, analysis and reporting of the trials. This practice is very expensive for society and also likely leads to loss of lives because the industry conceals harmful research results. It is imperative, not least for patients' safety, to ensure that all results of clinical trials become publicly available in their entirety, preferably including the trial protocol and the raw data, within a certain time limit after the termination of the trial. Every planned trial should therefore be registered in an international database with a unique identification number. In accordance with national recommendations, as well as with the views of the Association for the Danish Pharmaceutical Industry and the Danish Medical Association, far more public funds should be made available for clinical trials. This could ensure that the research is relevant to patients, that the treatment in the control group is relevant, that the effect measures are relevant, and that the research is planned and analysed in a fair manner, for example by blinding during data analysis and the writing of the report.